AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22018587 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants (reference group)
Number of subjects: 830
Study 18446122 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic Impedance ratio (TTIr) measured using the Bodystat Dual Scan 2005
Number of subjects: 23
Study 18446122 — intervention group
Group type: COMPARATOR
Intervention: Extravascular lung water (EVLW) and index (EVLWI) measured using the PiCCO system
Number of subjects: 23
Study 18386615 — intervention group
Group type: EXPERIMENTAL
Intervention: Romanian subjects
Number of subjects: 262
Study 12556015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial asthma patients
Number of subjects: 150
Study 12556015 — intervention group
Group type: COMPARATOR
Intervention: Other pulmonary disorder patients
Number of subjects: 150
Study 12556015 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 150
Study 12556015 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic males
Number of subjects: 150
Study 12556015 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic females
Number of subjects: 150
Study 10785225 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg/d)
Number of subjects: 70
Study 10785225 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (5 mg/d)
Number of subjects: 70
Study 9148355 — intervention group
Group type: EXPERIMENTAL
Intervention: Bair Hugger heater
Number of subjects: 27
Study 9148355 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 8380765 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA (gamma-linolenic acid) at a dose of 480 mg/day
Number of subjects: 111
Study 8380765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 2952426 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar bread (100 g guar/kg wheat flour)
Number of subjects: 16
Study 2952426 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar granulate (5 g twice daily providing 8.3 g guar/day)
Number of subjects: 16
Study 2952426 — intervention group
Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 16
Study 2952426 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar bread
Number of subjects: 16
Study 2952426 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar granulate
Number of subjects: 16
Study 29546659 — intervention group
Group type: COMPARATOR
Intervention: Automated adherence alert messages (alert)
Number of subjects: 179
Study 29546659 — intervention group
Group type: COMPARATOR
Intervention: Social support (partner)
Number of subjects: 179
Study 29546659 — intervention group
Group type: COMPARATOR
Intervention: Both social support and alerts (partner + alert)
Number of subjects: 179
Study 29546659 — intervention group
Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 179
Study 27758120 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser DARRT
Number of subjects: 20
Study 27758120 — intervention group
Group type: COMPARATOR
Intervention: Bullseye technique
Number of subjects: 20
Study 24861833 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 0
Study 24861833 — intervention group
Group type: COMPARATOR
Intervention: Sham moxa devices
Number of subjects: 0
Study 24458964 — intervention group
Group type: COMPARATOR
Intervention: IRC VAS
Number of subjects: 9
Study 24458964 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimless VAS
Number of subjects: 9
Study 20734132 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia, multimodal exercise program (strength, balance, and endurance training)
Number of subjects: 89
Study 20734132 — intervention group
Group type: COMPARATOR
Intervention: Sham flexibility and relaxation program
Number of subjects: 89
Study 17988889 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass
Number of subjects: 1054
Study 17988889 — intervention group
Group type: COMPARATOR
Intervention: Coronary angioplasty
Number of subjects: 1054
Study 16173889 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping condition - $50 vouchers on Wednesday and Friday for meeting quantitative urinalysis criteria and a $100 voucher on the following Monday for meeting qualitative criteria
Number of subjects: 0
Study 16173889 — intervention group
Group type: COMPARATOR
Intervention: Terminal condition - only the $100 earning opportunity for meeting the qualitative criteria
Number of subjects: 0
Study 16173889 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping condition
Number of subjects: 0
Study 16173889 — intervention group
Group type: COMPARATOR
Intervention: Terminal condition
Number of subjects: 0
Study 12771763 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg orally once a day)
Number of subjects: 50
Study 12771763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg orally once a day) + Tolterodine (2 mg orally twice daily)
Number of subjects: 50
Study 10852263 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved physical health after 6 months
Number of subjects: 90
Study 10852263 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved mental health after 6 months
Number of subjects: 90
Study 8659218 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative low molecular weight heparin (tinzaparin)
Number of subjects: 80
Study 8659218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1894930 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxudine 3% cream for 5 days
Number of subjects: 200
Study 1894930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 6222710 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin plus Clindamycin (TM/C)
Number of subjects: 100
Study 6222710 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam (MOX)
Number of subjects: 100
Study 31521449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin 0.3 mg/kg/8 hours
Number of subjects: 60
Study 31521449 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam 1 mg/kg/day divided into three doses
Number of subjects: 60
Study 31521449 — intervention group
Group type: EXPERIMENTAL
Intervention: Both melatonin and diazepam
Number of subjects: 60
Study 31521449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin
Number of subjects: 60
Study 31521449 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam
Number of subjects: 60
Study 30373644 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the 17-item CONSORT‐A checklist
Number of subjects: 622
Study 30373644 — intervention group
Group type: EXPERIMENTAL
Intervention: European Journal of Anesthesiology
Number of subjects: 622
Study 30373644 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia
Number of subjects: 622
Study 30373644 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial design adherence
Number of subjects: 622
Study 30373644 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact of authors (e-mail address)
Number of subjects: 622
Study 30373644 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment status
Number of subjects: 622
Study 30373644 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of participants analyzed
Number of subjects: 622
Study 30373644 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization
Number of subjects: 622
Study 30373644 — intervention group
Group type: EXPERIMENTAL
Intervention: Funding disclosure
Number of subjects: 622
Study 27457968 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid fish oil (6 meals/week)
Number of subjects: 99
Study 27457968 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated powder (conventional meals)
Number of subjects: 99
Study 27457968 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional meals and placebo powder)
Number of subjects: 99
Study 24468081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 12
Study 23207259 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA
Number of subjects: 50
Study 23207259 — intervention group
Group type: COMPARATOR
Intervention: Conventional TBNA
Number of subjects: 50
Study 23207259 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid‐based cytology
Number of subjects: 50
Study 23207259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell block specimens
Number of subjects: 50
Study 23207259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytopathologists' agreement
Number of subjects: 50
Study 21034626 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-oxidants group (vitamin C, vitamin E, Salvia Miltiorrhiza L)
Number of subjects: 4814
Study 21034626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medicine)
Number of subjects: 4814
Study 21034626 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-oxidants group (subgroup analysis)
Number of subjects: 4814
Study 21034626 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-oxidants group (high-risk factors)
Number of subjects: 4814
Study 21034626 — intervention group
Group type: COMPARATOR
Intervention: Control group (high-risk factors)
Number of subjects: 4814
Study 21034626 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific high-risk factors)
Number of subjects: 4814
Study 21034626 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-oxidants group (specific high-risk factors)
Number of subjects: 4814
Study 17067720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (150 microg/mL)
Number of subjects: 67
Study 17067720 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (10 mg/mL)
Number of subjects: 67
Study 15764007 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi-training
Number of subjects: 18
Study 15764007 — intervention group
Group type: COMPARATOR
Intervention: Control (relaxation)
Number of subjects: 18
Study 12063536 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) with raw peanut extract
Number of subjects: 363
Study 12063536 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE assay
Number of subjects: 363
Study 12063536 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of SPT and specific IgE assay
Number of subjects: 363
Study 12063536 — intervention group
Group type: COMPARATOR
Intervention: DBPCFC (Double-blind, placebo-controlled food challenges)
Number of subjects: 363
Study 11008920 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A1 I462V genotype
Number of subjects: 214
Study 11008920 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A1 I462V genotype with at least one valine allele
Number of subjects: 214
Study 11008920 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A1 I462V genotype with homozygous deletion of GSTM1
Number of subjects: 214
Study 11008920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CYP1A1 I462V mutation)
Number of subjects: 214
Study 9350363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain (2 mg.kg‐1) - Wound infiltration (Group A)
Number of subjects: 183
Study 9350363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain (2 mg.kg‐1) - Regional nerve blockade (Group B)
Number of subjects: 183
Study 9350363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain (2 mg.kg‐1) - Combination of wound infiltration and regional nerve blockade (Group C)
Number of subjects: 183
Study 9350363 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 183
Study 1491864 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.075% capsaicin
Number of subjects: 23
Study 1491864 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 23
Study 3858479 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 33
Study 3858479 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (betamethasone)
Number of subjects: 33
Study 31703146 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (cognitive‐behavioral strategies, mindfulness, values‐based activity)
Number of subjects: 85
Study 31703146 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 85
Study 30290765 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Robert Jones bandage (MRJB) compression therapy for 24 hours
Number of subjects: 90
Study 30290765 — intervention group
Group type: COMPARATOR
Intervention: No compression therapy (Control)
Number of subjects: 90
Study 27237764 — intervention group
Group type: EXPERIMENTAL
Intervention: mSMT treatment
Number of subjects: 16
Study 27237764 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 16
Study 24501162 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day saffron
Number of subjects: 105
Study 24501162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 24501162 — intervention group
Group type: COMPARATOR
Intervention: No capsule (non-placebo control)
Number of subjects: 105
Study 23430667 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise session (40 minutes, moderately intense, predominantly aerobic)
Number of subjects: 16
Study 23430667 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (no exercise)
Number of subjects: 16
Study 20004276 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg intraamniotic (1.0 IA)
Number of subjects: 52
Study 20004276 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg intrafetal (1.0 IF)
Number of subjects: 52
Study 20004276 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg intraamniotic (1.5 IA)
Number of subjects: 52
Study 20004276 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg intrafetal (1.5 IF)
Number of subjects: 52
Study 18029165 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO measurement using NIOX MINO®
Number of subjects: 0
Study 18029165 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO measurement for asthma management
Number of subjects: 0
Study 18029165 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO measurement for asthma management in severe population
Number of subjects: 0
Study 18029165 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostics
Number of subjects: 0
Study 16836070 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 56
Study 16836070 — intervention group
Group type: COMPARATOR
Intervention: Blunt dissection tonsillectomy
Number of subjects: 56
Study 12832959 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence with transdermal nicotine patch (25 mg per day)
Number of subjects: 78
Study 12832959 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence with placebo patch
Number of subjects: 78
Study 12832959 — intervention group
Group type: COMPARATOR
Intervention: Continuous smoking
Number of subjects: 78
Study 12832959 — intervention group
Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 78
Study 10800878 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 7
Study 8849265 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rhG‐CSF (lenograstim, 2 micrograms per kg of body weight per day)
Number of subjects: 12
Study 1462489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginally administered estriol at a dose of 0.01 g daily for 3 weeks, and 0.01 g bi‐weekly for a further 3 weeks
Number of subjects: 629
Study 1462489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginally administered estriol
Number of subjects: 629
Study 30326906 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management exercise program + spa therapy (5 sessions of self-management exercise, 18 sessions of spa therapy)
Number of subjects: 0
Study 30326906 — intervention group
Group type: COMPARATOR
Intervention: Information booklet + spa therapy (18 sessions of spa therapy)
Number of subjects: 0
Study 30326906 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management exercise program + spa therapy
Number of subjects: 0
Study 27756268 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training for nominated staff, peer support service establishment, training for additional teachers, mental health awareness session for all teachers.
Number of subjects: 0
Study 27756268 — intervention group
Group type: COMPARATOR
Intervention: Usual practice in comparison schools.
Number of subjects: 0
Study 24813833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain bias condition (threatening interpretation of pain)
Number of subjects: 106
Study 24813833 — intervention group
Group type: COMPARATOR
Intervention: No pain bias condition (nonthreatening interpretation of pain)
Number of subjects: 106
Study 24813833 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat condition (threatening information regarding the cold pressor)
Number of subjects: 106
Study 24813833 — intervention group
Group type: COMPARATOR
Intervention: Reassuring condition (reassuring information regarding the cold pressor)
Number of subjects: 106
Study 22569484 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg vaccine
Number of subjects: 539
Study 22569484 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 μg vaccine
Number of subjects: 539
Study 22569484 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg vaccine
Number of subjects: 539
Study 22569484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 20353751 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference formulation (20 mg leflunomide)
Number of subjects: 24
Study 20353751 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (20 mg leflunomide)
Number of subjects: 24
Study 20353751 — intervention group
Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 24
Study 18300351 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of H pylori-positive patients and all H pylori-positive family members (group I)
Number of subjects: 70
Study 18300351 — intervention group
Group type: COMPARATOR
Intervention: Treatment of H pylori-positive patients only (group II)
Number of subjects: 70
Study 15935245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study 15935245 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Exposure (PE)
Number of subjects: 0
Study 12566476 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO Group (Carbohydrate Group) consuming a diet with a CHO/protein ratio of 3.5 (68 g protein/d)
Number of subjects: 24
Study 12566476 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Group consuming a diet with a CHO/protein ratio of 1.4 (125 g protein/d)
Number of subjects: 24
Study 12566476 — intervention group
Group type: COMPARATOR
Intervention: Both groups (CHO and Protein)
Number of subjects: 24
Study 10588963 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 59
Study 10588963 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 59
Study 9346692 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (PGI2) at 5 ng/kg/minute
Number of subjects: 15
Study 9346692 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) at 0.1 microgram/kg/minute
Number of subjects: 15
Study 9346692 — intervention group
Group type: COMPARATOR
Intervention: Control interval (no drug)
Number of subjects: 15
Study 1678797 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy (laxatives plus behaviour modification)
Number of subjects: 169
Study 1678797 — intervention group
Group type: COMPARATOR
Intervention: Behaviour modification alone
Number of subjects: 169
Study 6192747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum, methotrexate, bleomycin
Number of subjects: 77
Study 6192747 — intervention group
Group type: COMPARATOR
Intervention: Oncovin, methotrexate, bleomycin
Number of subjects: 77
Study 30579763 — intervention group
Group type: COMPARATOR
Intervention: 6 months of androgen suppression plus radiotherapy (6AS+RT)
Number of subjects: 1071
Study 30579763 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 months of androgen suppression plus radiotherapy (18AS+RT)
Number of subjects: 1071
Study 30579763 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (18 months)
Number of subjects: 1071
Study 30579763 — intervention group
Group type: COMPARATOR
Intervention: No zoledronic acid
Number of subjects: 1071
Study 29161369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pace-capture-guided ablation along a contact-force-guided isolation line
Number of subjects: 156
Study 29161369 — intervention group
Group type: COMPARATOR
Intervention: Contact-force-guided PV isolation ablation alone (control group)
Number of subjects: 156
Study 29161369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pace-capture-guided ablation
Number of subjects: 156
Study 27825009 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (2 mg/kg per day, up to 100 mg for 2 months)
Number of subjects: 21
Study 27825009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 27825009 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 21
Study 24188873 — intervention group
Group type: EXPERIMENTAL
Intervention: Long GnRH agonist
Number of subjects: 111
Study 24188873 — intervention group
Group type: COMPARATOR
Intervention: Short GnRH agonist
Number of subjects: 111
Study 24188873 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 111
Study 23244163 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 hour psychoeducational intervention focusing on sleep
Number of subjects: 214
Study 23244163 — intervention group
Group type: COMPARATOR
Intervention: Set of booklets (control group)
Number of subjects: 214
Study 21180275 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 30
Study 21180275 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine Ringer's solution)
Number of subjects: 30
Study 21180275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 16804519 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 6111
Study 16804519 — intervention group
Group type: COMPARATOR
Intervention: Not treated (NRT)
Number of subjects: 6111
Study 12693876 — intervention group
Group type: EXPERIMENTAL
Intervention: FT+ (Feeling Thermometer with hypothetical marker states)
Number of subjects: 84
Study 12693876 — intervention group
Group type: COMPARATOR
Intervention: FT- (Feeling Thermometer without hypothetical marker states)
Number of subjects: 84